Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tg Therapeutics (TGTX) Cash from Investing Activities: 2016-2025

Historic Cash from Investing Activities for Tg Therapeutics (TGTX) over the last 10 years, with Sep 2025 value amounting to $46.4 million.

  • Tg Therapeutics' Cash from Investing Activities rose 596.71% to $46.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $45.2 million, marking a year-over-year increase of 173.44%. This contributed to the annual value of -$1.0 million for FY2024, which is 97.95% up from last year.
  • Per Tg Therapeutics' latest filing, its Cash from Investing Activities stood at $46.4 million for Q3 2025, which was up 1,261.40% from -$4.0 million recorded in Q2 2025.
  • Tg Therapeutics' 5-year Cash from Investing Activities high stood at $46.4 million for Q3 2025, and its period low was -$44.8 million during Q4 2023.
  • Over the past 3 years, Tg Therapeutics' median Cash from Investing Activities value was -$6.2 million (recorded in 2023), while the average stood at -$2.0 million.
  • Per our database at Business Quant, Tg Therapeutics' Cash from Investing Activities crashed by 8,396.30% in 2022 and then soared by 596.71% in 2025.
  • Over the past 5 years, Tg Therapeutics' Cash from Investing Activities (Quarterly) stood at $3.3 million in 2021, then soared by 394.80% to $16.3 million in 2022, then slumped by 375.09% to -$44.8 million in 2023, then surged by 135.28% to $15.8 million in 2024, then soared by 596.71% to $46.4 million in 2025.
  • Its Cash from Investing Activities stands at $46.4 million for Q3 2025, versus -$4.0 million for Q2 2025 and -$12.9 million for Q1 2025.